WASHINGTON, May 17 (Reuters) - Biopharmaceutical firm Amicus Therapeutics Inc. on Thursday set its planned initial public offering at 5 million shares for an estimated $14 to $16 each.
WASHINGTON, May 17 (Reuters) - Biopharmaceutical firm Amicus Therapeutics Inc. on Thursday set its planned initial public offering at 5 million shares for an estimated $14 to $16 each.